Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

PURPOSE: Nivolumab and pembrolizumab are antibodies against the programmed-death-receptor- 1 (PD-1) which are associated with distinct immune related adverse effects (AEs). This meta-analysis of randomized clinical trials aims to summarize current knowledge regarding the toxicity profile of these ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Ricardo, Carneiro, Benedito A., Agulnik, Mark, Rademaker, Alfred W., Pai, Sachin G., Villaflor, Victoria M., Cristofanilli, Massimo, Sosman, Jeffrey A., Giles, Francis J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352453/
https://www.ncbi.nlm.nih.gov/pubmed/27852042
http://dx.doi.org/10.18632/oncotarget.13315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352453/
https://www.ncbi.nlm.nih.gov/pubmed/27852042
http://dx.doi.org/10.18632/oncotarget.13315

Ejemplares similares